Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial

• Published in: Diabetes, obesity & metabolism Vol. 20; no. 1; pp. 200 - 205
• Main Authors: Lingvay, Ildiko, Harris, Stewart, Jaeckel, Elmar, Chandarana, Keval, Ranthe, Mattis F., Jódar, Esteban
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.2018; Wiley Subscription Services, Inc
• Subjects: Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - therapeutic use; Antidiabetics; Blood Glucose - analysis; Body Mass Index; Body weight gain; Body weight loss; Brief Report; Brief Reports; clinical trial; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Drug Combinations; Drug Monitoring; Drug Resistance, Multiple; Drug Therapy, Combination - adverse effects; Evidence-based medicine; Glycated Hemoglobin A - analysis; Hemoglobin; Humans; Hyperglycemia - prevention & control; Hypoglycemia; Hypoglycemia - chemically induced; Hypoglycemia - prevention & control; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; IDegLira; Incretins - administration & dosage; Incretins - adverse effects; Incretins - therapeutic use; Insulin; Insulin Glargine - adverse effects; Insulin Glargine - therapeutic use; insulin therapy; Insulin, Long-Acting - administration & dosage; Insulin, Long-Acting - adverse effects; Insulin, Long-Acting - therapeutic use; Liraglutide - administration & dosage; Liraglutide - adverse effects; Liraglutide - therapeutic use; Metformin - adverse effects; Metformin - therapeutic use; Obesity - blood; Obesity - complications; Obesity - drug therapy; Overweight - blood; Overweight - complications; Overweight - drug therapy; type 2 diabetes; Weight Gain - drug effects; Weight Loss; clinical trial; type 2 diabetes; insulin therapy; body mass index; IDegLira
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13043

This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26‐week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%‐2.5%), FPG (1.5%‐1.9%) and BMI categories (1.8%‐1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%‐87% vs 31%‐66%), FPG (71%‐74% vs 40%‐51%) and BMI categories (71%‐73% vs 40%‐54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.